Zhijun pharmaceutical's class 3 new drug oral sustained release suspension of daiyinamin will be approved soon

According to the public information released by the State Food and drug administration, the review status of class 3.2 new drugs of Shenzhen Zhijun pharmaceutical, a subsidiary of Sinopharm, will change to "in approval" after being reviewed by inamin oral sustained release suspension According to the review progress of new drugs, Sinopharm is expected to obtain the production approval documents of the drug within 2-3 months Daiyinamin is a compound preparation for the treatment of dry cough without phlegm and severe and frequent cough The head of the company told the big smart news agency that every 5ml of the drug contains 20mg of codeine and 4mg of chlorpheniramine Compared with the federal cough syrup, the advantage is that the combination of "antitussive + antihistamine" is more accurate "This medicine has definite clinical effect and good safety, which will provide a new choice for clinical medication." Industry insiders also predict that tbinamin is expected to become the upgraded product of the second largest variety of federal cough syrup in the pharmaceutical industry Sinopharm is mainly engaged in antibiotics and respiratory cough drugs in its current pharmaceutical industry business Last year, the company's industrial income declined slightly due to factors such as drug restriction At present, the company is actively reserving non antibiotic specialty drugs A researcher who is concerned about the company said that the quality of this variety is very good " In recent years, China's pharmaceutical industry has been in the same direction of transformation, with the approval of specialty drugs and the continuous enrichment of endogenous varieties, which will also be a reserve for the production of the industrial base next year.